Venous Thromboembolism - Drug Pipeline Analysis and Market Forecasts to 2016

The Venous Thromboembolism Therapeutics Market is Forecast to Show Moderate Growth Until 2016

Online PR News – 10-February-2010 – – GlobalData’s analysis suggests that the global venous thromboembolism (VTE) market was worth $1,535m in 2009. It is forecast to grow at a compound annual growth rate (CAGR) of 6.5% for the next seven years to reach $2,383m by 2016. This growth rate is primarily attributable to the strong current treatment options as well as strong pipeline candidates. This growth will be further supported by the high incidence rate of the disease, increased uptake of factor Xa inhibitor and direct thrombin inhibitor, and the launch of late-stage me-too candidates with improved efficacy and safety.

For further details, please click or add the below link to your browser:

GlobalData analyzed the current competitive landscape for VTE drugs and found the competition to be strong. There are more than 10 marketed products for the treatment of VTE, which includes anticoagulants and thrombolytics. Competition in the VTE market is driven not only by product characteristics such as their efficacy and safety profile, but also by market characteristics such as the number of competitors, pricing and generics. The VTE market is largely dominated by generic products (off-patent) which have a medium to high efficacy and safety profile. Although the current market has few branded products, there is a strong competition between generics and branded products. The efficacy of the currently marketed product is high in terms of reducing total VTE events, reducing proximal deep vein thrombosis (DVT) events and decreasing the risk of pulmonary embolism (PE). However, the current marketed products are associated with some of the serious side effects such as increased risk of hemorrhage and thrombocytopenia. This implies that new targeted therapies with improved efficacy and safety profile are required. The competition in VTE market will further intensify with the launch of strong pipeline products, which have improved efficacy and safety.

For further details, please click or add the below link to your browser:

GlobalData has found that the global VTE market is a lucrative market with moderate levels of unmet need. The VTE market has a number of products with high efficacy and safety profiles. Although most marketed products have an acceptable efficacy and safety profile, there lies an underlying opportunity to improve the therapeutic outcomes. Treatment options such as low-molecular-weight heparin (LMWH), vitamin K antagonists, factor Xa inhibitors, direct thrombin inhibitors and thrombolytics are effective in the management of VTE and the unmet need in term of efficacy is lower. However, the safety profiles of marketed products are moderate and have some rare but serious side effects such as hemorrhage and thrombocytopenia. In summation, the unmet need in the VTE market is moderate and can be fulfilled by products that target underserved patient populations and offer improved safety profile while being efficacious.

GlobalData, the industry analysis specialist, has released its latest research, “Venous Thromboembolism - Drug Pipeline Analysis and Market Forecasts to 2016”, which provides key data, information and analysis on the VTE market. The report provides a comprehensive overview of the annualized market data from 2001 to 2009, and forecasts forward seven years to 2016. The research also includes market characterization, opportunities, the unmet needs associated with VTE, a competitive assessment, product profiles of major marketed products and promising drugs in the pipeline, an overview on discontinued projects, implications for future market competition, and the key players of the VTE market.

For further details, please click or add the below link to your browser:

Or visit our report store: